T细胞亚群与静脉注射4.5g糖皮质激素治疗中重度甲状腺相关性眼病的临床活性和疗效相关

IF 1.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Endocrine Research Pub Date : 2023-07-03 DOI:10.1080/07435800.2023.2219734
Huixia Li, Bin Wang, Qin Li, Qing Li, Jie Qiao, Dongping Lin, Chunhua Sui, Lin Ye, Hualing Zhai, Boren Jiang, Ningjian Wang, Bing Han, Mengda Jiang, Xiaofeng Tao, Ziyang Shao, Chenfang Zhu, Yubo Ma, Ping Xiong, Jing Sun, Huifang Zhou, Yingli Lu
{"title":"T细胞亚群与静脉注射4.5g糖皮质激素治疗中重度甲状腺相关性眼病的临床活性和疗效相关","authors":"Huixia Li,&nbsp;Bin Wang,&nbsp;Qin Li,&nbsp;Qing Li,&nbsp;Jie Qiao,&nbsp;Dongping Lin,&nbsp;Chunhua Sui,&nbsp;Lin Ye,&nbsp;Hualing Zhai,&nbsp;Boren Jiang,&nbsp;Ningjian Wang,&nbsp;Bing Han,&nbsp;Mengda Jiang,&nbsp;Xiaofeng Tao,&nbsp;Ziyang Shao,&nbsp;Chenfang Zhu,&nbsp;Yubo Ma,&nbsp;Ping Xiong,&nbsp;Jing Sun,&nbsp;Huifang Zhou,&nbsp;Yingli Lu","doi":"10.1080/07435800.2023.2219734","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intravenous glucocorticoid (IVGC) remains the main treatment for moderate-to-severe and active thyroid-associated ophthalmopathy (TAO). However, a substantial number (20-30%) of active moderate-to-severe TAO patients may not respond to IVGC. Some patients may have disease progression despite IVGC treatment or relapse after steroid withdrawal.</p><p><strong>Objectives: </strong>To analyze risk factors for clinical activity and predictive factors for clinical outcomes of 4.5 g IVGC therapy in patients with moderate-to-severe TAO.</p><p><strong>Design and methods: </strong>Our study was performed in two steps: step 1 involved 110 moderate-to-severe TAO patients and analyzed risk factors for TAO activity; step 2 involved 53 active moderate-to-severe TAO patients from step 1 who were treated with 4.5 g IVGC therapy and analyzed predictive factors for clinical outcomes of IVGC therapy. Multivariate logistic regression analysis was used to identify the independent predictors and establish the predictive model.</p><p><strong>Results: </strong>Abnormal TRAb (OR = 4.717; <i>P</i> = 0.019) and the percentage of CD3+CD4+ T cell (OR = 1.092; <i>P</i> = 0.028) were independently associated with the activity of moderate-to-severe TAO patients. The pretreatment CAS-max in both eyes (OR = 7.221; <i>P</i> = 0.013) and the percentage of pretreatment CD3+T cell (OR = 0.718; <i>P</i> = 0.037) were independently associated with therapeutic efficacy. The pretreatment CAS-max in both eyes (OR = 156.53; <i>P</i> = 0.028) and the percentage of post-treatment CD3+T cell (OR = 0.554; <i>P</i> = 0.043) were independently associated with therapeutic efficacy. Besides, multivariable prediction models were established, which were better in the forecasting aspect than single-variable prediction models.</p><p><strong>Conclusions: </strong>Based on the findings of this study, we should monitor the peripheral blood T cell subsets for TAO, which could be helpful to timely judge the condition of clinical manifestation and effect of treatment for TAO patients. Multivariable prediction models have been established, which have great significance for clinical work.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"T Cell Subsets are Associated with Clinical Activity and Efficacy of 4.5g Intravenous Glucocorticoid for Moderate-To-Severe Thyroid-Associated Ophthalmopathy.\",\"authors\":\"Huixia Li,&nbsp;Bin Wang,&nbsp;Qin Li,&nbsp;Qing Li,&nbsp;Jie Qiao,&nbsp;Dongping Lin,&nbsp;Chunhua Sui,&nbsp;Lin Ye,&nbsp;Hualing Zhai,&nbsp;Boren Jiang,&nbsp;Ningjian Wang,&nbsp;Bing Han,&nbsp;Mengda Jiang,&nbsp;Xiaofeng Tao,&nbsp;Ziyang Shao,&nbsp;Chenfang Zhu,&nbsp;Yubo Ma,&nbsp;Ping Xiong,&nbsp;Jing Sun,&nbsp;Huifang Zhou,&nbsp;Yingli Lu\",\"doi\":\"10.1080/07435800.2023.2219734\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Intravenous glucocorticoid (IVGC) remains the main treatment for moderate-to-severe and active thyroid-associated ophthalmopathy (TAO). However, a substantial number (20-30%) of active moderate-to-severe TAO patients may not respond to IVGC. Some patients may have disease progression despite IVGC treatment or relapse after steroid withdrawal.</p><p><strong>Objectives: </strong>To analyze risk factors for clinical activity and predictive factors for clinical outcomes of 4.5 g IVGC therapy in patients with moderate-to-severe TAO.</p><p><strong>Design and methods: </strong>Our study was performed in two steps: step 1 involved 110 moderate-to-severe TAO patients and analyzed risk factors for TAO activity; step 2 involved 53 active moderate-to-severe TAO patients from step 1 who were treated with 4.5 g IVGC therapy and analyzed predictive factors for clinical outcomes of IVGC therapy. Multivariate logistic regression analysis was used to identify the independent predictors and establish the predictive model.</p><p><strong>Results: </strong>Abnormal TRAb (OR = 4.717; <i>P</i> = 0.019) and the percentage of CD3+CD4+ T cell (OR = 1.092; <i>P</i> = 0.028) were independently associated with the activity of moderate-to-severe TAO patients. The pretreatment CAS-max in both eyes (OR = 7.221; <i>P</i> = 0.013) and the percentage of pretreatment CD3+T cell (OR = 0.718; <i>P</i> = 0.037) were independently associated with therapeutic efficacy. The pretreatment CAS-max in both eyes (OR = 156.53; <i>P</i> = 0.028) and the percentage of post-treatment CD3+T cell (OR = 0.554; <i>P</i> = 0.043) were independently associated with therapeutic efficacy. Besides, multivariable prediction models were established, which were better in the forecasting aspect than single-variable prediction models.</p><p><strong>Conclusions: </strong>Based on the findings of this study, we should monitor the peripheral blood T cell subsets for TAO, which could be helpful to timely judge the condition of clinical manifestation and effect of treatment for TAO patients. Multivariable prediction models have been established, which have great significance for clinical work.</p>\",\"PeriodicalId\":11601,\"journal\":{\"name\":\"Endocrine Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrine Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/07435800.2023.2219734\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07435800.2023.2219734","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:静脉注射糖皮质激素(IVGC)仍然是中重度和活动性甲状腺相关眼病(TAO)的主要治疗方法。然而,相当数量(20-30%)的活动性中重度TAO患者可能对IVGC没有反应。一些患者尽管接受了IVGC治疗,但仍可能出现疾病进展或类固醇停药后复发。目的:分析4.5 g IVGC治疗中重度TAO患者临床活动性的危险因素及临床转归的预测因素。设计与方法:本研究分为两步进行:第一步纳入110例中重度TAO患者,分析TAO活性的危险因素;步骤2纳入53例来自步骤1的活动性中重度TAO患者,接受4.5 g IVGC治疗,分析IVGC治疗临床结局的预测因素。采用多元logistic回归分析确定独立预测因子,建立预测模型。结果:TRAb异常(OR = 4.717;P = 0.019)和CD3+CD4+ T细胞百分比(OR = 1.092;P = 0.028)与中重度TAO患者的活动独立相关。预处理后两眼CAS-max (OR = 7.221;P = 0.013)和预处理CD3+T细胞百分比(OR = 0.718;P = 0.037)与疗效独立相关。预处理后两眼CAS-max (OR = 156.53;P = 0.028)和处理后CD3+T细胞百分比(OR = 0.554;P = 0.043)与疗效独立相关。建立了多变量预测模型,在预测方面优于单变量预测模型。结论:基于本研究结果,应监测TAO患者外周血T细胞亚群,有助于及时判断TAO患者的临床表现及治疗效果。建立了多变量预测模型,对临床工作具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
T Cell Subsets are Associated with Clinical Activity and Efficacy of 4.5g Intravenous Glucocorticoid for Moderate-To-Severe Thyroid-Associated Ophthalmopathy.

Background: Intravenous glucocorticoid (IVGC) remains the main treatment for moderate-to-severe and active thyroid-associated ophthalmopathy (TAO). However, a substantial number (20-30%) of active moderate-to-severe TAO patients may not respond to IVGC. Some patients may have disease progression despite IVGC treatment or relapse after steroid withdrawal.

Objectives: To analyze risk factors for clinical activity and predictive factors for clinical outcomes of 4.5 g IVGC therapy in patients with moderate-to-severe TAO.

Design and methods: Our study was performed in two steps: step 1 involved 110 moderate-to-severe TAO patients and analyzed risk factors for TAO activity; step 2 involved 53 active moderate-to-severe TAO patients from step 1 who were treated with 4.5 g IVGC therapy and analyzed predictive factors for clinical outcomes of IVGC therapy. Multivariate logistic regression analysis was used to identify the independent predictors and establish the predictive model.

Results: Abnormal TRAb (OR = 4.717; P = 0.019) and the percentage of CD3+CD4+ T cell (OR = 1.092; P = 0.028) were independently associated with the activity of moderate-to-severe TAO patients. The pretreatment CAS-max in both eyes (OR = 7.221; P = 0.013) and the percentage of pretreatment CD3+T cell (OR = 0.718; P = 0.037) were independently associated with therapeutic efficacy. The pretreatment CAS-max in both eyes (OR = 156.53; P = 0.028) and the percentage of post-treatment CD3+T cell (OR = 0.554; P = 0.043) were independently associated with therapeutic efficacy. Besides, multivariable prediction models were established, which were better in the forecasting aspect than single-variable prediction models.

Conclusions: Based on the findings of this study, we should monitor the peripheral blood T cell subsets for TAO, which could be helpful to timely judge the condition of clinical manifestation and effect of treatment for TAO patients. Multivariable prediction models have been established, which have great significance for clinical work.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Endocrine Research
Endocrine Research 医学-内分泌学与代谢
CiteScore
4.30
自引率
0.00%
发文量
10
审稿时长
>12 weeks
期刊介绍: This journal publishes original articles relating to endocrinology in the broadest context. Subjects of interest include: receptors and mechanism of action of hormones, methodological advances in the detection and measurement of hormones; structure and chemical properties of hormones. Invitations to submit Brief Reviews are issued to specific authors by the Editors.
期刊最新文献
Antithyroid Antibodies and Reproductive Parameters of Women with Hashimoto's Thyroiditis. Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma Treatment Outcomes in Patients with Recurrent Adrenocortical Carcinoma. Monogenic Diabetes: A Comprehensive Overview and Therapeutic Management of Subtypes of Mody. The Investigation of Kisspeptin, Spexin and Galanin in Euthyroid Women with Hashimoto's Thyroiditis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1